Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.49 |
| ▸ | CLK2 | P49760 | 2/20 | 0.49 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | MELK | Q14680 | 2/20 | 0.49 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.49 |
| ▸ | FECH | P22830 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8365703 | 0.87 | MKNK1 (0.60) | MAP3K5CSNK1DPRKD3MAP4K4MAPK9 | |
| SCHEMBL5372567 | 0.86 | ENPP2 (0.51) | MAP3K5CSNK1DPRKD3MAP4K4MAPK9 | |
| SCHEMBL5380918 | 0.86 | MAP2K4 (0.58) | MAP3K5CSNK1DPRKD3MAP4K4MAPK9 | |
| SCHEMBL14514437 | 0.86 | MAP2K4 (0.55) | MAP3K5CSNK1DPRKD3MAP4K4MAPK9 | |
| SCHEMBL5379398 | 0.85 | MAP3K5 (0.66) | MAP3K5CSNK1DPRKD3MAP4K4MAPK9 | |
| SCHEMBL7532041 | 0.84 | CLK2 (0.52) | MAP3K5CSNK1DPRKD3MAP4K4MAPK9 | |
| SCHEMBL5386487 | 0.82 | MAP4K4 (0.47) | MAP3K5CSNK1DPRKD3MAP4K4MAPK9 | |
| SCHEMBL5386179 | 0.82 | GSK3B (0.52) | MAP3K5CSNK1DPRKD3MAP4K4MAPK9 | |
| SCHEMBL5381317 | 0.80 | MAP4K4 (0.45) | MAP3K5CSNK1DPRKD3MAP4K4MAPK9 | |
| SCHEMBL5383013 | 0.80 | MAP2K4 (0.63) | MAP3K5CSNK1DPRKD3MAP4K4MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9511086-B2 | Method for improving immune system function by administering agents that inhibit DNA-dependent protein kinase-directed apoptosis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-12-06 | — | — | US | disclosed |
| US-20120039867-A1 | Immune System Function in Conditions Characterized by Elevated Double Strand Breaks | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
| EP-1487436-A4 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| US-7351729-B2 | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070149571-A1 | Combination therapy for treating or managing acute myelocytic leukemia | SIGNAL PHARMACEUTICALS, LLC | 2007-06-28 | — | — | US | disclosed |
| EP-1487436-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | Signal Pharmaceuticals, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040067953-A1 | Combination therapy for treating, preventing or managing proliferative disorders and cancers | SIGNAL PHARMACEUTICALS, LLC | 2004-04-08 | — | — | US | disclosed |
| WO-2003075917-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149571-A1 | Combination therapy for treating or managing acute myelocytic leukemia | MCL1, ATF1, MAP3K5 | MAP3K5 3/4885CSNK1D 736/4885PRKD3 179/4885 |
| US-20040067953-A1 | Combination therapy for treating, preventing or managing proliferative disorders and cancers | MAP3K1, MAP3K2, MAP2K2 | MAP3K5 6/4885CSNK1D 540/4885PRKD3 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.